» Articles » PMID: 32514891

Management of Psychiatric Disorders in Parkinson's Disease : Neurotherapeutics - Movement Disorders Therapeutics

Overview
Specialty Neurology
Date 2020 Jun 10
PMID 32514891
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Affective disorders (depression and anxiety), psychosis, impulse control disorders, and apathy are common and sometimes disabling psychiatric conditions in Parkinson disease (PD). Psychiatric aspects of PD are associated with numerous adverse outcomes, yet in spite of this and their high frequency, there remains incomplete understanding of epidemiology, presentation, risk factors, neural substrate, and management strategies. Psychiatric features are typically co- or multimorbid, and there is great intra- and interindividual variability in presentation [1]. The neuropathophysiological changes that occur in PD, as well as the association between PD treatment and particular psychiatric disorders, suggest a neurobiological contribution to many psychiatric symptoms. There is evidence that psychiatric disorders in PD are still under-recognized and undertreated, and although psychotropic medication use is common, randomized controlled trials demonstrating efficacy and tolerability are largely lacking. Future research on neuropsychiatric complications in PD should be oriented toward determining modifiable correlates or risk factors, and most importantly, establishing efficacious and well-tolerated treatment strategies.

Citing Articles

The Prevalence of Depressive Symptoms in Patients with Idiopathic Parkinson's Disease: Cross-Sectional Study from Somalia.

Sheikh Hassan M, Mohamed N, Yucel Y, Mohamed Y, Gokgul A Int J Gen Med. 2024; 17:5059-5068.

PMID: 39526067 PMC: 11550689. DOI: 10.2147/IJGM.S493161.


Treatment of Parkinson's Disease Psychosis-A Systematic Review and Multi-Methods Approach.

Rose O, Huber S, Trinka E, Pachmayr J, Clemens S Biomedicines. 2024; 12(10).

PMID: 39457629 PMC: 11505035. DOI: 10.3390/biomedicines12102317.


Impulse Control Disorders in Parkinson's Disease: An Overview of Risk Factors, Pathogenesis and Pharmacological Management.

Carbone F, Djamshidian A CNS Drugs. 2024; 38(6):443-457.

PMID: 38613665 PMC: 11098885. DOI: 10.1007/s40263-024-01087-y.


Non-Pharmacological Interventions for Depression and Anxiety in Parkinson's Disease.

van Wegen E, van Balkom T, Hirsch M, Rutten S, van den Heuvel O J Parkinsons Dis. 2024; 14(s1):S135-S146.

PMID: 38607762 PMC: 11380297. DOI: 10.3233/JPD-230228.


Pimavanserin: A Truly Effective Treatment for Parkinson's Disease Psychosis? A Review of Interventions.

Heim B, Peball M, Krismer F, Djamshidian A, Seppi K Neuropsychiatr Dis Treat. 2023; 19:1303-1312.

PMID: 37274140 PMC: 10239266. DOI: 10.2147/NDT.S371641.


References
1.
Sauerbier A, Jenner P, Todorova A, Chaudhuri K . Non motor subtypes and Parkinson's disease. Parkinsonism Relat Disord. 2015; 22 Suppl 1:S41-6. DOI: 10.1016/j.parkreldis.2015.09.027. View

2.
Antonini A, Chaudhuri K, Boroojerdi B, Asgharnejad M, Bauer L, Grieger F . Impulse control disorder related behaviours during long-term rotigotine treatment: a post hoc analysis. Eur J Neurol. 2016; 23(10):1556-65. PMC: 5096013. DOI: 10.1111/ene.13078. View

3.
Smith K, Xie S, Weintraub D . Incident impulse control disorder symptoms and dopamine transporter imaging in Parkinson disease. J Neurol Neurosurg Psychiatry. 2015; 87(8):864-70. PMC: 4854795. DOI: 10.1136/jnnp-2015-311827. View

4.
Richard I, McDermott M, Kurlan R, Lyness J, Como P, Pearson N . A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology. 2012; 78(16):1229-36. PMC: 3324323. DOI: 10.1212/WNL.0b013e3182516244. View

5.
Reijnders J, Scholtissen B, Weber W, Aalten P, Verhey F, Leentjens A . Neuroanatomical correlates of apathy in Parkinson's disease: A magnetic resonance imaging study using voxel-based morphometry. Mov Disord. 2010; 25(14):2318-25. DOI: 10.1002/mds.23268. View